Catalyst Database

Investigator initiated trial (UChicago Med). 5/7/24- First participant dosed. 10/29/24- Announced positive initial data. 1/13/25- Report long-term follow up data in 2025.

Suspected Mover: GALAXIES Lung-201/Lung 301 trial. Collab w/ GSK. 11/12/24- Interim data in 2025. 11/12/24 - GALAXIES Lung-301 enrollment ongoing. EMA granted clearance to advance 400mg as recommended Ph3 dose.

2/5/24- Completed Part A of Ph1/2 trial and initiated Part B. Enroll and dose patients in Part B. 2/10/25- Part B full-dose data in 2025.

IIT Trial. 3/24/25- Begin enrolling participants in April 2025 and provide initial clinical data in 2025.

ENTRIGUE/ENTRUST trials. 6/28/22- ENTRIGUE data reported and additional data presented at ACC/WCC 2023. 5/23/23- ENTRUST trial initiated. 02/29/24- Topline data in 2025.

Big Mover: 12/13/22- Data reported. 1/2025- Topline data in 2025.

ARISE trial & ARISE-2 study. Topline data in 2025. 03/18/24- Company acquired by BMY.

DELIVER trial: 5/20/24- Reported new data at Virtual Investor Event. 10/9/24- New data at WMS '24. 3/16/25- New long-term data & presentation at MDA '25 on Mar 19th. Registrational Expansion Cohort fully enrolled with data in late 2025.

Collab w/ MD Anderson. 5/21/24- Dose escalation part ongoing. Complete of dose escalation in 2024, initiation of dose expansion part, and presentation of first data 2025.

9/4/24 Continue to monitor patients for long-term remissions. 11/25/24- Results reported at SNO 2024. 3/13/25- Report additional findings at upcoming medical meetings in 2025.